Alivecor Inc. has focused on bringing medical-grade ECG technology to consumers. At the American Heart Association's Scientific Sessions in Chicago, the startup had a slew of studies comparing its ECG smartphone or smartwatch technology favorably to standard, hospital-based cardiology testing including 12-lead ECGs and implantable loop recorders.
Despite difficulties years ago, Medtronic plc has opted to pursue a pivotal trial program for its Symplicity Spyral renal denervation system to treat high blood pressure. To that end, it now is slated to start a clinical trial in medicated, uncontrolled hypertension patients, following on a trial initiated earlier this year in unmedicated hypertensive patients.
Near the start of this year, Mimedx Group Inc. looked poised to stretch up toward a $2 billion valuation. But it has struggled to right itself all year, since in February it became clear that the regenerative and therapeutic biologics maker was subject to a U.S. Department of Justice (DoJ) investigation of its sales and marketing practices, including undisclosed payments to doctors.
San Diego-based Resmed Inc. is slated to purchase long-term care EHR provider Matrixcare for $750 million. This acquisition is the latest move in an effort by the respiratory care company to expand its presence as a software-as-a-service (SaaS) provider outside of the traditional hospital setting.
Surgical implant company RTI Surgical Inc. will buy motion preservation-focused spinal implant player Paradigm Spine LLC for up to $300 million in cash and stock. The Alachua, Fla.-based small-cap company will pay $150 million when the deal closes, plus up to $150 million in potential milestone payments.
Traditional microfluidics undergirds advances in genomics, proteomics and point-of-care diagnostics. It allows the manipulation and analysis of tiny amounts of liquids on a microchip-like structure. But now microfluidics may be ready to go macro, as Massachusetts Institute of Technology (MIT) researchers have developed a new technological metaphor as a model – moving from a chip to fiber.
Wall Street doesn't typically embrace med-tech IPOs for companies without at least one product on the market that's generating significant revenues. But even in a volatile stock market, it's made an exception for Axonics Modulation Technologies Inc. The clinical-stage med-tech firm has raised $120 million in an IPO to back its rechargeable sacral neuromodulation (r-SNM) system to treat patients with overactive bladder (OAB), fecal incontinence (FI) or urinary retention (UR).
